Literature DB >> 20452916

Clarifying metformin's role and risks in liver dysfunction.

Carolyn C Brackett1.   

Abstract

OBJECTIVES: To explore why some clinicians hesitate to use metformin in patients with liver disease and whether routine monitoring of transaminases before and during metformin therapy is substantiated. DATA SOURCES: A Medline literature search was conducted (1966 to June 2008) using the terms metformin, lactic acidosis, liver disease, chronic liver disease, hepatotoxicity, hypoxia, risks, and predisposing factors. DATA SYNTHESIS: Manufacturer prescribing information and some current medical and lay press literature caution against metformin use in patients with liver disease. This recommendation is interpreted variably by different prescribers, with some believing that the caution implies metformin can cause or worsen liver injury. Others believe that liver disease predisposes patients to developing lactic acidosis. A clearer understanding of how and when to screen for liver dysfunction in patients before and during metformin therapy is thus warranted.
CONCLUSION: Metformin does not appear to cause or exacerbate liver injury and, indeed, is often beneficial in patients with nonalcoholic fatty liver disease. Nonalcoholic fatty liver frequently presents with transaminase elevations but should not be considered a contraindication to metformin use. Literature evidence of liver disease being associated with metformin-associated metabolic acidosis is largely represented by case reports. Most such patients had cirrhosis and were also actively using alcohol. Patients with cirrhosis, particularly those with encephalopathy, may have arterial hypoxemia, which heightens the risk of developing lactic acidosis. For this reason, identifying patients with cirrhosis before initiating metformin seems prudent. Because cirrhosis can exist in the face of normal liver transaminases, however, and because metformin is not considered intrinsically hepatotoxic, withholding metformin from patients with abnormal transaminases or routinely monitoring transaminases before or during metformin treatment is not supported.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20452916     DOI: 10.1331/JAPhA.2010.08090

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  13 in total

Review 1.  Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination?

Authors:  Moon-Sun Kim; Madeleine Ong; Xianqin Qu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes.

Authors:  Xiaodan Zhang; William S Harmsen; Teresa A Mettler; W Ray Kim; Rosebud O Roberts; Terry M Therneau; Lewis R Roberts; Roongruedee Chaiteerakij
Journal:  Hepatology       Date:  2014-07-31       Impact factor: 17.425

3.  Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma.

Authors:  Nitya Nathwani; Joycelynne Palmer; Timothy W Synold; Behrouz Salehian; Michael Rosenzweig; James F Sanchez; Samantha N Hammond; Kehinde Adekola; Valeria Tomarchio; Arnab Chowdhury; Chatchada Karanes; Myo Htut; Firoozeh Sahebi; Tanya Siddiqi; Amrita Krishnan; Stephen J Forman; Steven T Rosen
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-05-29

4.  Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice.

Authors:  Inmaculada García-Ruiz; Pablo Solís-Muñoz; Erica Gómez-Izquierdo; María Teresa Muñoz-Yagüe; Angela M Valverde; José A Solís-Herruzo
Journal:  J Biol Chem       Date:  2012-04-09       Impact factor: 5.157

Review 5.  Metformin and metabolic diseases: a focus on hepatic aspects.

Authors:  Juan Zheng; Shih-Lung Woo; Xiang Hu; Rachel Botchlett; Lulu Chen; Yuqing Huo; Chaodong Wu
Journal:  Front Med       Date:  2015-02-12       Impact factor: 4.592

6.  Editor's Highlight: Metformin Protects Against Acetaminophen Hepatotoxicity by Attenuation of Mitochondrial Oxidant Stress and Dysfunction.

Authors:  Kuo Du; Anup Ramachandran; James L Weemhoff; Hemantkumar Chavan; Yuchao Xie; Partha Krishnamurthy; Hartmut Jaeschke
Journal:  Toxicol Sci       Date:  2016-08-25       Impact factor: 4.849

7.  Metformin-induced hepatotoxicity.

Authors:  Francisco Miralles-Linares; Susana Puerta-Fernandez; M Rosa Bernal-Lopez; Francisco J Tinahones; Raul J Andrade; Ricardo Gomez-Huelgas
Journal:  Diabetes Care       Date:  2012-03       Impact factor: 19.112

8.  Hypoglycemia and severe lactic acidosis in a dog following metformin exposure.

Authors:  Nicole Barrella; Beth Eisenberg; Stephanie Nicole Simpson
Journal:  Clin Case Rep       Date:  2017-11-13

Review 9.  Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment.

Authors:  Kalyan Kumar Gangopadhyay; Parminder Singh
Journal:  Indian J Endocrinol Metab       Date:  2017 Mar-Apr

Review 10.  Diabetes and Hepatitis C: A Two-Way Association.

Authors:  Sara Salehi Hammerstad; Shira Frankel Grock; Hanna J Lee; Alia Hasham; Nina Sundaram; Yaron Tomer
Journal:  Front Endocrinol (Lausanne)       Date:  2015-09-14       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.